Loading organizations...
§ Private Profile · Dublin, Ireland
Nuritas is a technology company.
Nuritas has raised $151.6M across 7 funding rounds.
Key people at Nuritas.
Nuritas has raised $151.6M in total across 7 funding rounds.
Through cutting edge, AI-precision technology, Nuritas is creating a brand-new category of precision, cell-signaling peptide ingredients from nature.
Key people at Nuritas.
Nuritas has raised $151.6M in total across 7 funding rounds.
Nuritas's investors include NEO, SVG Ventures-THRIVE, VantagePoint Capital Partners, Marc Benioff, Randall Lewis, CPA, Ali Partovi, Paul Hewson (Bono), Cultivian Sandbox Ventures, Stephan Dolezalek, Nutresa Ventures, Temasek, VisVires New Protein.
Nuritas is a biotechnology company that uses artificial intelligence (AI) and genomics to discover and develop natural bioactive peptides with significant health benefits. Its proprietary AI platform, called the *AI Magnifier*, identifies novel peptides from plant-based food proteins, which are then developed into functional ingredients for use in dietary supplements, functional foods and beverages, cosmetics, and animal nutrition. Nuritas serves food and beverage companies, health and wellness sectors, and cosmetics brands by providing patented, clinically validated ingredients that address health issues such as muscle recovery, skin aging, sleep quality, and metabolic health. The company has demonstrated strong growth momentum, recently launching patented ingredients like PeptiStrong™ for muscle health and PeptiYouth™ for skin regeneration, and expanding its commercial presence internationally, including in the US[1][2][3][4][5][6].
Founded in 2014 by Dr. Nora Khaldi, a mathematician with a PhD in molecular evolution and bioinformatics, Nuritas emerged from the idea of revolutionizing ingredient discovery by applying AI to unlock peptides that traditional methods could not efficiently identify. Early traction included proving the AI model’s accuracy through clinical trials with over 80% success and attracting high-profile investors such as Bono, The Edge, and Marc Benioff. The company has grown rapidly since its launch, building a large peptide library of over six million candidates and securing multiple patents. Its evolution has included expanding from discovery to commercialization, with a focus on clinical validation and regulatory compliance to bring new, plant-based bioactive ingredients to market[3][5][7].
Nuritas rides the convergence of AI, biotechnology, and personalized nutrition trends. The timing is critical as consumer demand grows for natural, effective, and scientifically validated health ingredients, alongside rising interest in plant-based products and longevity solutions. Market forces such as advances in AI, genomics, wearable health tech, and regulatory acceptance favor Nuritas’ approach. By integrating AI-driven discovery with clinical science, Nuritas influences the broader ecosystem by setting new standards for ingredient innovation, accelerating product development, and enabling personalized nutrition and wellness solutions that respond to epigenetic and lifestyle data[4][6].
Looking ahead, Nuritas aims to expand its ingredient portfolio targeting major health areas like cardiometabolic health, neurocognition, bone and cartilage health, and energy. The company plans to leverage wearable technologies and personalized medicine to demonstrate and optimize the benefits of its peptides directly to consumers. As AI and biotechnology continue to evolve, Nuritas is well-positioned to lead the next generation of intelligent, natural ingredients that improve health outcomes on a global scale. Its influence is likely to grow as it bridges cutting-edge science with consumer products, potentially transforming how health and wellness ingredients are discovered, validated, and commercialized[3][4][6].
Nuritas has raised $151.6M across 7 funding rounds. Most recently, it raised $42.0M Series C in December 2024.
